Lifecare ASA

Lifecare ASA: Updated company presentation

Bergen, Norway, 23 April 2025 - Lifecare ASA (LIFE), a medtech company

developing next generation continuous glucose monitoring (CGM) solutions for

diabetes management, today publishes an updated company presentation

articulating the company's long-term value creation opportunity.

The presentation is attached and available at: https://lifecare.no/investor/

Key highlights from the presentation:

Diabetes is a trillion-dollar global healthcare challenge

* CGMs the fastest growing diabetes tech segment, representing a USD 30

billion market opportunity

* Within CGMs, implantable solutions represent a USD 5 billion potential

market

Strong value drivers in place 2025-2028

* Set to capitalize on "second mover" advantage, leveraging first mover

regulatory approvals in the US

* Capital efficient path to commercialization with partner-led go-to-market

strategy and minimal additional R&D

* Near-term value inflection points including veterinary market launch late

2025, CE mark in 2026, and European human market launch in 2027

Significant value creation potential

* Peak revenue potential of USD 1 billion + on realistic market assumptions

* Revenue sustainable at high levels long-term assuming conservative market

share in a growing market

* EBITDA margin of 35%+

About us

Lifecare ASA is a medical sensor company developing technology for sensing and

monitoring of various body analytes. Lifecare's main focus is to bring the

next generation of Continuous Glucose Monitoring ("CGM") systems to market.

Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor

technology is referred to as "Sencell" and is suitable for identifying and

monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, [email protected], +47 40 05 90 40

Renete Kaarvik, CFO, [email protected], +47 94 83 82 42

AI Terminal